HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Astria Therapeutics (NASDAQ:ATXS) and maintained a $20 price target.
August 08, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astria Therapeutics has received a reiterated 'Buy' rating and a maintained $20 price target from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Astria Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100